CA2953732C - Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor - Google Patents

Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Download PDF

Info

Publication number
CA2953732C
CA2953732C CA2953732A CA2953732A CA2953732C CA 2953732 C CA2953732 C CA 2953732C CA 2953732 A CA2953732 A CA 2953732A CA 2953732 A CA2953732 A CA 2953732A CA 2953732 C CA2953732 C CA 2953732C
Authority
CA
Canada
Prior art keywords
braf
seq
nras
mutation
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2953732A
Other languages
English (en)
French (fr)
Other versions
CA2953732A1 (en
Inventor
Mitchell Paul LEVESQUE
Reinhard DUMMER
Daniel Widmer
Marieke Ineke Geertje Raaijmakers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2953732(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of CA2953732A1 publication Critical patent/CA2953732A1/en
Application granted granted Critical
Publication of CA2953732C publication Critical patent/CA2953732C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CA2953732A 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Active CA2953732C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176944.8 2014-07-14
EP14176944 2014-07-14
PCT/EP2015/065986 WO2016008853A1 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Publications (2)

Publication Number Publication Date
CA2953732A1 CA2953732A1 (en) 2016-01-21
CA2953732C true CA2953732C (en) 2023-09-26

Family

ID=51210291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953732A Active CA2953732C (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Country Status (7)

Country Link
US (1) US20190194757A1 (enExample)
EP (1) EP3169797B2 (enExample)
JP (1) JP7036594B2 (enExample)
CN (1) CN107148481A (enExample)
CA (1) CA2953732C (enExample)
ES (1) ES2751925T5 (enExample)
WO (1) WO2016008853A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018213302A1 (en) 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法
US20240288397A1 (en) * 2021-06-23 2024-08-29 Royal Melbourne Institute Of Technology Conductometric sensor for detecting a nucleic acid and a method for the detection thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
EP3249053A1 (en) * 2009-03-27 2017-11-29 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
US20130315934A1 (en) * 2010-10-28 2013-11-28 Yale University Methods and Compositions for Assessing and Treating Cancer
WO2012061683A2 (en) 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer
CN104689318A (zh) * 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Also Published As

Publication number Publication date
WO2016008853A1 (en) 2016-01-21
CN107148481A (zh) 2017-09-08
EP3169797A1 (en) 2017-05-24
EP3169797B1 (en) 2019-08-21
EP3169797B2 (en) 2025-02-19
ES2751925T5 (en) 2025-05-13
US20190194757A1 (en) 2019-06-27
JP7036594B2 (ja) 2022-03-15
CA2953732A1 (en) 2016-01-21
JP2017529094A (ja) 2017-10-05
ES2751925T3 (es) 2020-04-02

Similar Documents

Publication Publication Date Title
Lignitto et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1
Cherry et al. Alternative splicing and cancer: insights, opportunities, and challenges from an expanding view of the transcriptome
Gao et al. Biology and clinical implications of the 19q13 aggressive prostate cancer susceptibility locus
Carvalho et al. Lack of microRNA‐101 causes E‐cadherin functional deregulation through EZH2 up‐regulation in intestinal gastric cancer
Cai et al. ZFX mediates non-canonical oncogenic functions of the androgen receptor splice variant 7 in castrate-resistant prostate cancer
Hua et al. Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19
Lin et al. Genetic interactions reveal distinct biological and therapeutic implications in breast cancer
Adler et al. An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth
Miyanaga et al. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing
Liu et al. Rare deleterious germline variants and risk of lung cancer
Barbieri et al. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity
Flynn et al. Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
EP3169797B1 (en) Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
WO2012040614A1 (en) Compositions and methods for detecting cancer metastasis
KR20180108820A (ko) 암 후생유전적 프로파일링
Galvan et al. Germline polymorphisms and survival of lung adenocarcinoma patients: a genome‐wide study in two European patient series
Tian et al. NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression
de Bony et al. Comprehensive identification of long noncoding RNAs in colorectal cancer
Yang et al. GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression
Gara et al. GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3
Jin et al. Circular RNA circDNA2 upregulates CCDC6 expression to promote the progression of gastric cancer via miR-149-5p suppression
Tombolan et al. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma
Van Goubergen et al. Targeting the CLK 2/SRSF 9 splicing axis in prostate cancer leads to decreased ARV 7 expression
Chen et al. The genetics of splicing in neuroblastoma
Bersani et al. Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170103

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260618

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260618